{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T20:20:33Z","timestamp":1790022033624,"version":"4.0.1"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"13","license":[{"start":{"date-parts":[[2021,7,29]],"date-time":"2021-07-29T00:00:00Z","timestamp":1627516800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,7,29]],"date-time":"2021-07-29T00:00:00Z","timestamp":1627516800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["R01CA228760-01A1"],"award-info":[{"award-number":["R01CA228760-01A1"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009624","name":"Veterans of Foreign Wars Auxiliary","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009624","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1245\/s10434-021-10382-7","type":"journal-article","created":{"date-parts":[[2021,7,29]],"date-time":"2021-07-29T14:02:59Z","timestamp":1627567379000},"page":"8556-8564","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Interferon Alpha-Expressing Oncolytic Adenovirus for Treatment of Esophageal Adenocarcinoma"],"prefix":"10.1245","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9808-1405","authenticated-orcid":false,"given":"Christopher J.","family":"LaRocca","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda O.","family":"Salzwedel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mizuho","family":"Sato-Dahlman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margarita V.","family":"Romanenko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafael","family":"Andrade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Davydova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masato","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,7,29]]},"reference":[{"key":"10382_CR1","doi-asserted-by":"crossref","unstructured":"Arnold M, Abnet CC, Neale RE, et al. Global burden of 5 major types of gastrointestinal cancer. Gastroenterology. Apr 2 2020.","DOI":"10.1053\/j.gastro.2020.02.068"},{"issue":"9864","key":"10382_CR2","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1016\/S0140-6736(12)60643-6","volume":"381","author":"A Pennathur","year":"2013","unstructured":"Pennathur A, Gibson MK, Jobe BA, Luketich JD. Oesophageal carcinoma. Lancet. 2013;381(9864):400\u201312.","journal-title":"Lancet"},{"issue":"1","key":"10382_CR3","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21590","volume":"70","author":"RL Siegel","year":"2020","unstructured":"Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020;70(1):7\u201330.","journal-title":"CA Cancer J Clin"},{"issue":"2","key":"10382_CR4","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1093\/jnci\/dji024","volume":"97","author":"H Pohl","year":"2005","unstructured":"Pohl H, Welch HG. The role of overdiagnosis and reclassification in the marked increase of esophageal adenocarcinoma incidence. J Natl Cancer Inst. 2005;97(2):142\u20136.","journal-title":"J Natl Cancer Inst"},{"issue":"2","key":"10382_CR5","doi-asserted-by":"publisher","first-page":"55","DOI":"10.14740\/wjon1254","volume":"11","author":"EO Then","year":"2020","unstructured":"Then EO, Lopez M, Saleem S, et al. Esophageal cancer: an updated surveillance epidemiology and end results database analysis. World J Oncol. 2020;11(2):55\u201364.","journal-title":"World J Oncol"},{"issue":"4","key":"10382_CR6","doi-asserted-by":"publisher","first-page":"232","DOI":"10.3322\/caac.21185","volume":"63","author":"J Lagergren","year":"2013","unstructured":"Lagergren J, Lagergren P. Recent developments in esophageal adenocarcinoma. CA Cancer J Clin. 2013;63(4):232\u201348.","journal-title":"CA Cancer J Clin"},{"key":"10382_CR7","doi-asserted-by":"crossref","unstructured":"Quint LE, Bogot NR. Staging esophageal cancer. Cancer Imaging. 2008;8 Spec No A:S33-42.","DOI":"10.1102\/1470-7330.2008.9007"},{"issue":"2","key":"10382_CR8","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.soc.2012.12.006","volume":"22","author":"CR Mulligan Jr","year":"2013","unstructured":"Mulligan CR Jr. Multidisciplinary management of esophageal cancer. Surg Oncol Clin N Am. 2013;22(2):217\u201346.","journal-title":"Surg Oncol Clin N Am"},{"issue":"11","key":"10382_CR9","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1016\/S1470-2045(19)30456-5","volume":"20","author":"M Arnold","year":"2019","unstructured":"Arnold M, Rutherford MJ, Bardot A, et al. Progress in cancer survival, mortality, and incidence in seven high-income countries 1995\u20132014 (ICBP SURVMARK-2): a population-based study. Lancet Oncol. 2019;20(11):1493\u2013505.","journal-title":"Lancet Oncol"},{"issue":"22","key":"10382_CR10","doi-asserted-by":"publisher","first-page":"2074","DOI":"10.1056\/NEJMoa1112088","volume":"366","author":"P van Hagen","year":"2012","unstructured":"van Hagen P, Hulshof MC, van Lanschot JJ, et al. Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med. 2012;366(22):2074\u201384.","journal-title":"N Engl J Med"},{"issue":"4","key":"10382_CR11","doi-asserted-by":"publisher","first-page":"261","DOI":"10.2165\/00063030-200216040-00003","volume":"16","author":"M Decatris","year":"2002","unstructured":"Decatris M, Santhanam S, O\u2019Byrne K. Potential of interferon-alpha in solid tumours: part 1. BioDrugs. 2002;16(4):261\u201381.","journal-title":"BioDrugs"},{"issue":"8","key":"10382_CR12","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1016\/0360-3016(87)90189-1","volume":"13","author":"LR Holsti","year":"1987","unstructured":"Holsti LR, Mattson K, Niiranen A, et al. Enhancement of radiation effects by alpha interferon in the treatment of small cell carcinoma of the lung. Int J Radiat Oncol Biol Phys. 1987;13(8):1161\u20136.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"18","key":"10382_CR13","first-page":"5735","volume":"50","author":"S Wadler","year":"1990","unstructured":"Wadler S, Wersto R, Weinberg V, Thompson D, Schwartz EL. Interaction of fluorouracil and interferon in human colon cancer cell lines: cytotoxic and cytokinetic effects. Cancer Res. 1990;50(18):5735\u20139.","journal-title":"Cancer Res"},{"issue":"6\u20137","key":"10382_CR14","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1016\/j.biochi.2007.04.006","volume":"89","author":"M Ferrantini","year":"2007","unstructured":"Ferrantini M, Capone I, Belardelli F. Interferon-alpha and cancer: mechanisms of action and new perspectives of clinical use. Biochimie. 2007;89(6\u20137):884\u201393.","journal-title":"Biochimie"},{"issue":"2","key":"10382_CR15","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1200\/JCO.1992.10.2.269","volume":"10","author":"D Kelsen","year":"1992","unstructured":"Kelsen D, Lovett D, Wong J, et al. Interferon alfa-2a and fluorouracil in the treatment of patients with advanced esophageal cancer. J Clin Oncol. 1992;10(2):269\u201374.","journal-title":"J Clin Oncol"},{"issue":"9","key":"10382_CR16","doi-asserted-by":"publisher","first-page":"2197","DOI":"10.1002\/1097-0142(19950501)75:9<2197::AID-CNCR2820750902>3.0.CO;2-S","volume":"75","author":"DH Ilson","year":"1995","unstructured":"Ilson DH, Sirott M, Saltz L, et al. A phase II trial of interferon alpha-2A, 5-fluorouracil, and cisplatin in patients with advanced esophageal carcinoma. Cancer. 1995;75(9):2197\u2013202.","journal-title":"Cancer"},{"issue":"11 Suppl 2","key":"10382_CR17","first-page":"S11","volume":"46","author":"JM Koeller","year":"1989","unstructured":"Koeller JM. Biologic response modifiers: the interferon alfa experience. Am J Hosp Pharm. 1989;46(11 Suppl 2):S11-15.","journal-title":"Am J Hosp Pharm"},{"issue":"25","key":"10382_CR18","doi-asserted-by":"publisher","first-page":"2780","DOI":"10.1200\/JCO.2014.58.3377","volume":"33","author":"RH Andtbacka","year":"2015","unstructured":"Andtbacka RH, Kaufman HL, Collichio F, et al. Talimogene laherparepvec improves durable response rate in patients with advanced melanoma. J Clin Oncol. 2015;33(25):2780\u20138.","journal-title":"J Clin Oncol"},{"issue":"5","key":"10382_CR19","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1016\/j.amjsurg.2012.02.016","volume":"204","author":"L Armstrong","year":"2012","unstructured":"Armstrong L, Arrington A, Han J, et al. Generation of a novel, cyclooxygenase-2-targeted, interferon-expressing, conditionally replicative adenovirus for pancreatic cancer therapy. Am J Surg. 2012;204(5):741\u201350.","journal-title":"Am J Surg"},{"issue":"1","key":"10382_CR20","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.surg.2012.02.017","volume":"152","author":"L Armstrong","year":"2012","unstructured":"Armstrong L, Davydova J, Brown E, Han J, Yamamoto M, Vickers SM. Delivery of interferon alpha using a novel Cox2-controlled adenovirus for pancreatic cancer therapy. Surgery. 2012;152(1):114\u201322.","journal-title":"Surgery"},{"issue":"26","key":"10382_CR21","doi-asserted-by":"publisher","first-page":"18041","DOI":"10.18632\/oncotarget.24710","volume":"9","author":"AO Salzwedel","year":"2018","unstructured":"Salzwedel AO, Han J, LaRocca CJ, Shanley R, Yamamoto M, Davydova J. Combination of interferon-expressing oncolytic adenovirus with chemotherapy and radiation is highly synergistic in hamster model of pancreatic cancer. Oncotarget. 2018;9(26):18041\u201352.","journal-title":"Oncotarget"},{"key":"10382_CR22","doi-asserted-by":"crossref","unstructured":"Davydova J, Yamamoto M. Oncolytic adenoviruses: design, generation, and experimental procedures. Curr Protoc Hum Genet. Jul 2013;Chapter 12:Unit 12 14.","DOI":"10.1002\/0471142905.hg1214s78"},{"issue":"1","key":"10382_CR23","first-page":"198","volume":"59","author":"KC Zimmermann","year":"1999","unstructured":"Zimmermann KC, Sarbia M, Weber AA, Borchard F, Gabbert HE, Schror K. Cyclooxygenase-2 expression in human esophageal carcinoma. Cancer Res. 1999;59(1):198\u2013204.","journal-title":"Cancer Res"},{"issue":"12","key":"10382_CR24","doi-asserted-by":"publisher","first-page":"4319","DOI":"10.1158\/0008-5472.CAN-04-0064","volume":"64","author":"J Davydova","year":"2004","unstructured":"Davydova J, Le LP, Gavrikova T, Wang M, Krasnykh V, Yamamoto M. Infectivity-enhanced cyclooxygenase-2-based conditionally replicative adenoviruses for esophageal adenocarcinoma treatment. Cancer Res. 2004;64(12):4319\u201327.","journal-title":"Cancer Res"},{"issue":"2","key":"10382_CR25","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1111\/j.1349-7006.2009.01407.x","volume":"101","author":"J Davydova","year":"2010","unstructured":"Davydova J, Gavrikova T, Brown EJ, et al. In vivo bioimaging tracks conditionally replicative adenoviral replication and provides an early indication of viral antitumor efficacy. Cancer Sci. 2010;101(2):474\u201381.","journal-title":"Cancer Sci"},{"issue":"2","key":"10382_CR26","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1006\/viro.2002.1772","volume":"305","author":"K Doronin","year":"2003","unstructured":"Doronin K, Toth K, Kuppuswamy M, Krajcsi P, Tollefson AE, Wold WS. Overexpression of the ADP (E3\u201311.6K) protein increases cell lysis and spread of adenovirus. Virology. 2003;305(2):378\u201387.","journal-title":"Virology"},{"issue":"13","key":"10382_CR27","doi-asserted-by":"publisher","first-page":"6147","DOI":"10.1128\/JVI.74.13.6147-6155.2000","volume":"74","author":"K Doronin","year":"2000","unstructured":"Doronin K, Toth K, Kuppuswamy M, Ward P, Tollefson AE, Wold WS. Tumor-specific, replication-competent adenovirus vectors overexpressing the adenovirus death protein. J Virol. 2000;74(13):6147\u201355.","journal-title":"J Virol"},{"issue":"10","key":"10382_CR28","doi-asserted-by":"publisher","first-page":"6839","DOI":"10.1128\/jvi.70.10.6839-6846.1996","volume":"70","author":"VN Krasnykh","year":"1996","unstructured":"Krasnykh VN, Mikheeva GV, Douglas JT, Curiel DT. Generation of recombinant adenovirus vectors with modified fibers for altering viral tropism. J Virol. 1996;70(10):6839\u201346.","journal-title":"J Virol"},{"issue":"3","key":"10382_CR29","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1111\/j.1349-7006.2007.00408.x","volume":"98","author":"H Hara","year":"2007","unstructured":"Hara H, Kobayashi A, Yoshida K, et al. Local interferon-alpha gene therapy elicits systemic immunity in a syngeneic pancreatic cancer model in hamster. Cancer Sci. 2007;98(3):455\u201363.","journal-title":"Cancer Sci"},{"issue":"4","key":"10382_CR30","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1016\/S0016-5085(03)01196-X","volume":"125","author":"M Yamamoto","year":"2003","unstructured":"Yamamoto M, Davydova J, Wang M, et al. Infectivity enhanced, cyclooxygenase-2 promoter-based conditionally replicative adenovirus for pancreatic cancer. Gastroenterology. 2003;125(4):1203\u201318.","journal-title":"Gastroenterology"},{"issue":"5","key":"10382_CR31","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1016\/j.surg.2015.01.006","volume":"157","author":"CJ LaRocca","year":"2015","unstructured":"LaRocca CJ, Han J, Gavrikova T, et al. Oncolytic adenovirus expressing interferon alpha in a syngeneic Syrian hamster model for the treatment of pancreatic cancer. Surgery. 2015;157(5):888\u201398.","journal-title":"Surgery"},{"key":"10382_CR32","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.oraloncology.2016.02.014","volume":"56","author":"CJ LaRocca","year":"2016","unstructured":"LaRocca CJ, Han J, Salzwedel AO, et al. Oncolytic adenoviruses targeted to Human Papilloma Virus-positive head and neck squamous cell carcinomas. Oral Oncol. 2016;56:25\u201331.","journal-title":"Oral Oncol"},{"issue":"44","key":"10382_CR33","doi-asserted-by":"publisher","first-page":"76044","DOI":"10.18632\/oncotarget.18340","volume":"8","author":"M Sato-Dahlman","year":"2017","unstructured":"Sato-Dahlman M, Miura Y, Huang JL, et al. CD133-targeted oncolytic adenovirus demonstrates anti-tumor effect in colorectal cancer. Oncotarget. 2017;8(44):76044\u201356.","journal-title":"Oncotarget"},{"issue":"1","key":"10382_CR34","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1038\/mt.2012.205","volume":"21","author":"Y Miura","year":"2013","unstructured":"Miura Y, Yamasaki S, Davydova J, et al. Infectivity-selective oncolytic adenovirus developed by high-throughput screening of adenovirus-formatted library. Mol Ther. 2013;21(1):139\u201348.","journal-title":"Mol Ther"},{"issue":"24","key":"10382_CR35","doi-asserted-by":"publisher","first-page":"8697","DOI":"10.1158\/1078-0432.CCR-04-1166","volume":"10","author":"TO Kirby","year":"2004","unstructured":"Kirby TO, Rivera A, Rein D, et al. A novel ex vivo model system for evaluation of conditionally replicative adenoviruses therapeutic efficacy and toxicity. Clin Cancer Res. 2004;10(24):8697\u2013703.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10382_CR36","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/s40169-018-0214-5","volume":"7","author":"CJ LaRocca","year":"2018","unstructured":"LaRocca CJ, Warner SG. Oncolytic viruses and checkpoint inhibitors: combination therapy in clinical trials. Clin Transl Med. 2018;7(1):35.","journal-title":"Clin Transl Med"},{"issue":"6","key":"10382_CR37","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1038\/cgt.2008.103","volume":"16","author":"M Anders","year":"2009","unstructured":"Anders M, Rosch T, Kuster K, et al. Expression and function of the coxsackie and adenovirus receptor in Barrett\u2019s esophagus and associated neoplasia. Cancer Gene Therapy. 2009;16(6):508\u201315.","journal-title":"Cancer Gene Therapy"},{"issue":"5","key":"10382_CR38","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1038\/sj.cgt.7700313","volume":"8","author":"DA Heideman","year":"2001","unstructured":"Heideman DA, Snijders PJ, Craanen ME, et al. Selective gene delivery toward gastric and esophageal adenocarcinoma cells via EpCAM-targeted adenoviral vectors. Cancer Gene Therapy. 2001;8(5):342\u201351.","journal-title":"Cancer Gene Therapy"},{"issue":"5","key":"10382_CR39","doi-asserted-by":"publisher","first-page":"1651","DOI":"10.1073\/pnas.88.5.1651","volume":"88","author":"HS Ginsberg","year":"1991","unstructured":"Ginsberg HS, Moldawer LL, Sehgal PB, et al. A mouse model for investigating the molecular pathogenesis of adenovirus pneumonia. Proc Natl Acad Sci USA. 1991;88(5):1651\u20135.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"1","key":"10382_CR40","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1099\/0022-1317-40-1-45","volume":"40","author":"SJ Duncan","year":"1978","unstructured":"Duncan SJ, Gordon FC, Gregory DW, et al. Infection of mouse liver by human adenovirus type 5. J Gen Virol. 1978;40(1):45\u201361.","journal-title":"J Gen Virol"},{"key":"10382_CR41","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/B978-0-12-398342-8.00003-3","volume":"115","author":"WS Wold","year":"2012","unstructured":"Wold WS, Toth K. Chapter three\u2013Syrian hamster as an animal model to study oncolytic adenoviruses and to evaluate the efficacy of antiviral compounds. Adv Cancer Res. 2012;115:69\u201392.","journal-title":"Adv Cancer Res"},{"issue":"1","key":"10382_CR42","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1186\/s12929-018-0468-7","volume":"25","author":"NP Lee","year":"2018","unstructured":"Lee NP, Chan CM, Tung LN, Wang HK, Law S. Tumor xenograft animal models for esophageal squamous cell carcinoma. J Biomed Sci. 2018;25(1):66.","journal-title":"J Biomed Sci"}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-021-10382-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1245\/s10434-021-10382-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-021-10382-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,14]],"date-time":"2021-11-14T15:17:15Z","timestamp":1636903035000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1245\/s10434-021-10382-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,29]]},"references-count":42,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["10382"],"URL":"https:\/\/doi.org\/10.1245\/s10434-021-10382-7","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,29]]},"assertion":[{"value":"9 November 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 June 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 July 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"None.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosure"}}]}}